BeyondSpring (NASDAQ:BYSI – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.52, FiscalAI reports.
BeyondSpring Trading Down 15.8%
Shares of BeyondSpring stock opened at $0.84 on Friday. The business’s 50 day simple moving average is $1.38 and its 200-day simple moving average is $1.49. The stock has a market capitalization of $34.50 million, a price-to-earnings ratio of -5.99 and a beta of 0.48. BeyondSpring has a twelve month low of $0.73 and a twelve month high of $2.44.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in BeyondSpring stock. State Street Corp purchased a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring at the end of the most recent quarter. 40.29% of the stock is owned by institutional investors.
About BeyondSpring
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
See Also
- Five stocks we like better than BeyondSpring
- Microsoft’s Maia 300 Chip Targets NVIDIA’s AI Dominance
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
